Skip to main content

Advertisement

Table 2 Treatment exposure and tolerance

From: Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

  Arm A (n = 18) Arm B (n = 24) p-value
Cycles of paclitaxel: median (range) 6 (2–6) 6 (1–6)
Relative dose intensity of paclitaxel: median (range) 0.94 (0.68–1.11) 0.88 (0.55–1.03)
Number of bevacizumab injections: median (range) 9 (1–39)
Related adverse events (Grade ≥ 3): n (%)a 2 (11.1) 10 (41.7) 0.03
  1. aGraded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0